Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 9/20 | 0.50 |
| ▸ | METAP1 | P53582 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478153 | 0.87 | METAP2 (0.51) | METAP2METAP1KDM4E | |
| SCHEMBL6477252 | 0.80 | METAP2 (0.66) | METAP2METAP1 | |
| SCHEMBL6935924 | 0.78 | METAP2 (0.40) | METAP2METAP1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL6489481 | 0.73 | METAP2 (0.50) | METAP2METAP1 | |
| SCHEMBL6563460 | 0.73 | METAP2 (0.47) | METAP2METAP1 | |
| SCHEMBL6935912 | 0.73 | METAP2 (0.42) | METAP2METAP1 | |
| SCHEMBL6477441 | 0.73 | METAP2 (0.47) | METAP2METAP1 | |
| SCHEMBL6476471 | 0.72 | METAP2 (0.49) | METAP2METAP1 | |
| SCHEMBL6485409 | 0.70 | METAP2 (0.47) | METAP2METAP1SMN1; SMN2GAA | |
| SCHEMBL6477893 | 0.70 | METAP2 (0.47) | METAP2METAP1KDM4ESMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | claimed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | claimed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | claimed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | claimed |
| US-6956060-B2 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-10-18 | — | — | US | disclosed |
| US-6630514-B2 | Administering N-propargyl-1-aminoindan | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-10-07 | — | — | US | disclosed |
| US-6316504-B1 | ADMINISTERING R(+)-N-PROPARGYL-1-AMINOINDAN OR ITS SALT FOR THERAPY OF MULTIPLE SCLEROSIS | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885KDM4E 1796/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885KDM4E 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.